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a  b  s  t  r  a  c  t
A  recent  clinical  trial of  a live-attenuated  tetravalent  chimeric  yellow  fever-dengue  vaccine  afforded
no  protection  against  disease  caused  by  dengue  2  (DENV-2).  This outcome  was  unexpected  as  two  or
more  doses  of this  vaccine  had  raised  broad  neutralizing  antibody  responses.  Data  from  pre-clinical
subhuman  primate  studies  revealed  that vaccination  with  the  monotypic  DENV-2  component  failed  to
meet  established  criteria  for solid  protection  to  homotypic  live virus  challenge.  Accordingly,  it  is suggested
that  preclinical  testing  adopt  more  rigorous  criteria  for protection  and  that Phase  I  testing  be  extended
to  require  evidence  of  solid  monotypic  protective  immunity  for each  component  of a dengue  vaccine  by
direct  challenge  with  live-attenuated  DENV.  Because  live-attenuated  tetravalent  DENV  vaccines  exhibitengue  hemorrhagic fever
accine
accine  challenge
accine protection
ntibodies
 cells
evidence  of  immunological  interference  phenomena,  during  Phase  II, volunteers  given  mixtures  of  DENV
1–4  vaccines  should  be separately  challenged  with  monotypic  live-attenuated  DENV.  Immune  responses
to  live-attenuated  challenge  viruses  and  vaccine  strains  should  be  studied  in an  attempt  to develop  useful
in  vitro  correlates  of in  vivo  protection.  Finally,  it  will be  important  to learn  if DENV  non-structural  protein
1  (NS1)  contributes  to  pathogenesis  of the  vascular  permeability  syndrome  in  humans.  If so,  immunity
to  dengue  1–4  NS1  may  be  crucial  to  prevent  severe  disease.© 2013 The Author. Published by Elsevier Ltd. 
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Open access under CC BY license.. Introduction
Because standard public health measures have proved insuf-
cient to contain the 20–21st century dengue pandemic, major
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Open access under CC BY license.control efforts have been directed to developing effective and
safe vaccines [1–5]. Five candidates are or have been in stages of
human testing and one, a phase IIb clinical trial of the sanoﬁpasteur
tetravalent chimeric dengue-yellow fever vaccine (CYD 23), has
proceeded to a test of efﬁcacy in humans [6–10]. In the CYD 23
trial, from studies of a small random sample it was estimated that
90% of enrolled Thai children circulated neutralizing antibodies
from previous Japanese encephalitis (JE) vaccination or wild-type
DENV or JE infections. Despite this background ﬂavivirus immunity
and signiﬁcant boosts in DENV 1–4 neutralizing antibodies after
2 or 3 doses of vaccine neither the initial, second nor third dose
of vaccine protected against DENV-2 disease [10,11]. Although
4502 S.B. Halstead / Vaccine 31 (2013) 4501– 4507
Table 1
Dengue illnesses observed in children given CYD vaccine or placebo following one, two  or three doses or after any dose (Intention to Treat) shown by type of dengue virus
recovered [10].
Doses DENV Dengue Vaccine Control Efﬁcacy (95% C.I.) P value*
At risk** Cases At risk** Cases
>28 days after 3rd dose 1 2536 9 1251 10 55.6 0.1
2 2510 31 1250 17 9.2 0.8
3 2541 1 1257 2 75.3 0.5
4 2542 0 1263 4 100 0.02
>28  days after 2nd dose, before 3rd dose 1 1018 1 510 4 87.5 0.083
2 1014 12 509 3 −101 0.406
3 1018 1 510 4 87.5 0.083
4 1019 0 511 0 –
After 1 and before 2nd dose 1 1290 4 645 1 −99.9 0.876
2 1290 6 644 4 25.1 0.909
3 1291 2 643 5 80.1 0.082
4 1291 0 645 1 100 0.723
Intention  to treat 1 5343 14 2666 18 61.2 (17.4–82.1 0.01
2 5312 52 2622 27 3.5 (−59.8–40.5) 0.9
3 5348 4 2667 11 81.9 (38.8–95.8) 0.0026
4 5353 1 2679 5 90.0 (10.6–99.8) 0.03
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* Two-tailed chi square with Yates correction.
** Person-years at risk.
umbers are small, successive doses of vaccine resulted in no
bvious trend for increased protection against disease with DENV
1, -3 or -4 (Table 1). When cases from all post-immunization
eriods were combined (intention to treat) individual protective
fﬁcacy for DENV-1 was 61.3, for DENV-3 was 82.0 and for DENV-4
as 90.0, all judged statistically signiﬁcant by the study’s authors
Table 1). Additional results for this vaccine from the many other
linical trials now in progress should harden these data.
Following conventional vaccine development strategies, the low
fﬁcacy of the sanoﬁpasteur vaccine was not recognized until for-
al  clinical efﬁcacy trials. Fortunately, there is much to be learned
rom the CYD23 clinical trial that, if acted upon, may  save time and
educe the cost of identifying new protective constructs. Here, the
YD 23 trial results are analyzed to identify possible mechanisms
nderlying reduced protective efﬁcacy and to make suggestions of
ow live virus vaccines tests in humans should be modiﬁed per-
itting early demonstration of vaccine efﬁcacy, identiﬁcation of
orrelates of vaccine protection and, if necessary, recompose vac-
ines or redesign administration schedules to achieve improved
omotypic, heterotypic and multitypic DENV protective efﬁcacy.
he empirical nature of this process is noted.
. Protective dengue immunity
In the design of vaccines and immunization schemes to protect
gainst the four DENV it was recognized that natural protection
gainst dengue infection and/or disease is observed under three
ircumstances: (1) monotypic, (2) heterotypic and (3) multitypic
mmunity. Evidence for these types of immunity and what is known
bout mechanisms are brieﬂy reviewed:
1) Monotypic immunity In experimental animals, CD8+ T cells con-
tribute  importantly to the containment of a primary DENV
infection  [12]. Solid and presumably lifelong protection against
re-infection with the same DENV ensues following a primary
dengue  infection. This has been proved by challenge of human
immunes  with homotypic live DENV [13–16]. This protec-
tive  immunity has been attributed to antibodies as monotypic
immune serum protected against lethal encephalitis in mice by
homotypic DENV and against dengue fever in humans [17–19].
Also,  it has been established that passive transfer of monoclonalantibodies to DENV envelope proteins or to domain III protected
against  intracerebral challenge with homotypic live virus in
mice  [20]. It is important to note that in monotypic immune
monkeys a homotypic live virus challenge was followed by
absence  of viremia and no anamnestic antibody response, a
response  labeled “solid immunity” [21,22]. Other workers have
extended  these observations to rhesus monkeys and humans
showing  an absence of viremia and stable neutralizing antibody
responses  following homotypic live DENV challenges of mono-
typic  immune individuals [23,24]. The long-term stability of
circulating  antibodies in the face of revaccination has also been
demonstrated in vaccinia-immune humans [25]. Excitingly, a
quaternary structure on the intact virion has been identiﬁed as
an attachment site for monotypic DENV neutralizing antibodies
[26,27].
(2) Heterotypic immunity Sabin observed that susceptible adult
American  volunteers convalescent from overt DENV-1 infec-
tions  were refractory to DENV-2 infection for 3 months,
experiencing modiﬁed disease for up to 9 months [16]. The
shorter  the interval between DENV-1 infection and DENV-
2  challenge, the greater the protection. Similar phenomena
have been observed in other settings. For example, a live-
attenuated DENV-1 mouse brain vaccine given during an
on-going  1963 epidemic in Puerto Rico produced a protec-
tive  efﬁcacy of 39% against DENV-3 dengue fever (DF). [28]
Modiﬁcation of enhanced disease severity accompanying a
second  dengue infection occurs commonly as evidenced in
several  settings. In Iquitos, Peru in 1995, a large DENV-2 out-
break  followed the prior introduction of DENV-1 in 1990.
These  are the conditions for the occurrence of DHF/DSS,
but no cases were observed. [29] Compellingly, the 1995
infecting virus, a DENV-2 American genotype, was uniformly
neutralized in vitro by DENV-1 immune sera from Iquitos
residents. [30] Aotus monkeys immune to DENV-1 showed
signiﬁcant protection against viremic American genotype
DENV-2 infection compared with viremias in susceptible con-
trols.  [31] A similar phenomenon was  observed in Cuba
where the severity of DENV-2 disease in DENV-1-immunes
increased as the interval between infections increased from
4  to 20 years [32]. In vitro, DENV-2 neutralization by
DENV-1-immune sera was  greater at shorter than at longer
ine 31
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intervals. In sum, the ability of human DENV-1 antibodies
to  neutralize DENV-2 continuously declined over time [33].
Whether  suppression of symptoms at short and longer inter-
vals  results from the same mechanism(s) remains to be
clariﬁed.
Heterotypic immunity has been studied experimentally in a
mouse  model. Infections with DENV-1 then DENV-2 or DENV-2
then  DENV-4, protected against secondary heterologous DENV
infection  at intervals of 4 to 52 weeks. Passive transfer of DENV-
immune  serum protected against replication of heterologous
challenge virus in all tissues tested, whereas adoptive transfer
of  DENV-immune cells signiﬁcantly protected mice from repli-
cation  of the challenge virus only when a lower inoculum was
administered [34,35].
Infection  with DENV-1 was able to completely protect AG129
mice  from lethal DENV-2 infection when given at an interval
of  6–8 weeks (the Sabin experiment) [36]. Neither antibod-
ies  nor B or T cells alone or in combination could explain the
strong  heterotypic protective immunity demonstrated. Curi-
ously,  adoptive transfer of DENV-1-immune memory B cells
blocked  DENV-2 invasion of the central nervous system but did
not  prevent the capillary leak syndrome. The authors attributed
heterotypic protective immunity to a form of cellular innate
immunity (NK cells, ADCC or Toll receptor-mediated) that was
blocked  by treating animals with cyclophosphamide. In theory,
as  NK cells are interferon dependent, they may  not have been
properly  activated in AG or A 129 mice. As a result of such data
the  role or necessity for T cell immunity in acquired heterotypic
protective immunity has been controversial. Recent data from
a  humanized mouse model of infection and disease and from
humans  infected with dengue in Sri Lanka, however, strongly
suggest  that T cells are a component of heterotypic or multitypic
and  vaccine-derived protection [37,38].
One approach to measuring vaccine derived heterotypic
immunity might be to exploit the observations of Kliks et al.
who  studied low-dilution sera for their ability to neutralize
dengue virus in primary human monocytes [39]. Sera had been
collected  prior to a second DENV 2 infection from 33 children
with  inapparent infections and 7 who were hospitalized. A
majority  of pre-infection sera from silent infections neutral-
ized  DENV 2 while most sera from hospitalized children either
enhanced  DENV 2 infection or failed to neutralize. The use of
a  Fc-receptor bearing cell system as an alternative to classical
neutralization tests to studying vaccine-induced immunity has
been recommended by others [40].
3)  Multitypic immunity It has long been observed that DHF/DSS
occurred during the second but not subsequent heterotypic
DENV infections; that is, disease severity is suppressed during
a  third or fourth DENV infection [41]. That second, not third or
fourth  dengue infections resulted in hospitalization for DHF was
supported by mathematical analysis of the shape of the age-
speciﬁc  hospitalization curve in Thailand [42]. Additional data
derive  from an analysis of 15,825 children hospitalized with
laboratory-conﬁrmed dengue at the Kamphaeng Phet Provin-
cial  Hospital and Queen Sirikit National Institute of Child Health
in  Bangkok. In these studies no children with a third or fourth
DENV  infection were hospitalized for DHF/DSS. There were,
however,  6 of 105 DHF patients (5.7%) admitted twice with a
dengue  infection whose serological response was compatible
with  a third or fourth dengue infection [43]. A more compre-
hensive analysis of DENV neutralizing antibody responses of
participants  in a large prospective cohort study in Iquitos, Peru
documented  a marked reduction in overt illness accompanying
a  third or fourth DENV infections [80].
Sequential dengue infections with two  or more DENV in
humans  raise neutralizing antibodies to three or four DENV (2013) 4501– 4507 4503
[44]. It has been an uninspected assumption of the dengue
vaccine community that administering multiple doses of a
tetravalent  dengue vaccine (resulting in broadly cross-reactive
DENV neutralizing antibodies) will provide protection compa-
rable  to that of sequential DENV infections. However, sequential
monotypic DENV infections may  result in a different immune
response than do sequential doses of a tetravalent vaccine. In
mice  infected with DENV-1 then DENV-2, memory B cells spe-
ciﬁc  to DENV-2 were detected demonstrating that in addition
to  stimulating DENV-1 memory B cells antibodies speciﬁc to
the  second virus were also produced [36]. Plasma cells circu-
lating  antibodies speciﬁc to a heterotypic DENV have also been
detected  in humans [45].
3. Hypotheses explaining reduced CYD 23 vaccine efﬁcacy
Interference. By design, it was  hoped that, when given as a
mixture, each component of chimeric live-attenuated DENV vac-
cine would be independently processed to result in four different
monotypic immune responses [4]. It was believed that initial pre-
sentation and processing by the immune system provided the
best chance for a live dengue virus to raise monotypic protec-
tive immunity. However, interference manifested by assymetrical
immunological responses to mixtures of four vaccine viruses was
recognized by the developers of the CYD vaccine and studied in
cynomolgous monkeys [46]. Indeed, failure of symmetrical produc-
tion of neutralizing antibodies to each of the four DENV has been
reported for all live-attenuated viruses given as mixtures [8,47–50].
In early studies, conducted before GMP manufacturing seeds
were produced, monovalent DENV-1 (10 4.5), DENV-2 (103.0),
DENV-3 (103.6), and DENV-4 (104.4) vaccines given to susceptible
rhesus monkeys each resulted viremia in some animals [51]. How-
ever, when mixtures of four viruses were given together at a single
site, only DENV-4 viremia was detected consistently. Mixtures of
all four DENV vaccines at relatively low-titers were given to six
animals GMT  neutralizing antibody titers to DENV1 - 3 were 6–20-
fold lower than GMT  in animals that had been given a mixture
of wild-type DENV 1–4. However, DENV-4 neutralizing antibody
titers following administration of DENV-4 vaccine were equiva-
lent to those raised following infection with wild-type virus. It
was concluded that simultaneous administration of tetravalent
CYD vaccine produced a hierarchy of immune response: DENV-
4 > DENV-1 > DENV-3 > DENV-2. Indeed, usually only DENV-3 and
-4 viremia was detected following administration of the tetravalent
vaccine.
In an attempt to improve tetravalent neutralizing antibody
responses after initial immunization, bivalent vaccines were given
in each arm, but this approach did not signiﬁcantly alter the “inter-
ference pattern” immune response. [46] As demonstrated in this
and earlier studies when the four attenuated DENV were given
in one or two sites and then challenged with a second dose of
tetravalent vaccine several months later, a greater than four-fold
anamnestic neutralizing antibody response was  observed to DENV-
1, -2 and -3. However, DENV-4 neutralizing antibody responses
were not boosted [46,52]. This suggests that in monkeys, at least
for a period of several months, solid monotypic immunity did not
develop to DENV-1–3 but did to DENV-4. This protection may not
have been durable as challenge with CYD 1–4 one year after initial
immunization produced a signiﬁcant boost in neutralizing antibod-
ies to all four DENV [46]. Similar to these challenge data in monkeys,
susceptible adult humans, predominantly whites, given CYD 1–4
and given a second dose six months later produced anamnestic
neutralizing antibody responses to DENV 1–3, but not to DENV-4
[53].
Interference that resulted in reduced infection and immune
response to components of a mixture of live-attenuated viruses
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as been described and well studied with the three live-attenuated
olio viruses. This problem was effectively solved by changing the
oncentration ratio of each component, reducing the amount of the
ype of poliovirus that outgrew the others [54]. However, when
 reduced dose of the DENV-4 component in a tetravalent vac-
ine was given to susceptible monkeys this same outcome was not
chieved. In the animals that received a vaccine composed of 5 logs
f DENV 1, 2 and 3 but only 3 logs of DENV-4, DENV-4 viremia dis-
ppeared and the initial DENV-4 neutralizing antibody response
as severely blunted. A booster with DENV 1–4 vaccine given two
onths later resulted in DENV 1–4 seroconversions in 4/5 animals
46].
Incomplete monotypic immune protection. In CYD 23 neither
onotypic or heterotypic nor multitypic immunity against DENV-
 disease was achieved after administration of one or successive
oses. Early in its pre-clinical development the CY DENV-2 vaccine
as tested for ability to raise homotypic protective immunity in
usceptible rhesus monkeys [55]. Susceptible animals, four each,
ere inoculated separately with 105, 104, 103, and 102 pfu of
himeric DENV-2. This resulted in viremic infections and moderate
evels of speciﬁc neutralizing antibodies. Sixty-three days later ani-
als were challenged with 105 pfu of wild-type DENV 2 (S-16803).
o viremia was detected in these monkeys (experimental details
ere not provided), but all animals experienced greater than four-
old anamnestic-type neutralizing antibody responses. At the time,
he authors concluded that immunization with chimeric DENV-2
esulted in protection to homologous challenge. However, this con-
lusion is at odds with a consensus from earlier monkey and human
tudies where “solid” protective immune response to homologous
ive DENV challenge was characterized by absence of viremia plus
bsence of an anamnestic response. [21–24] No published chal-
enge studies of monkeys immunized with monovalent DENV-1,
3 and -4 vaccines have been found. Nor were studies performed
tudying the effect of interval between vaccination and challenge
n the duration of monotypic DENV vaccine protective efﬁcacy.
Susceptible  and yellow fever-immune adult humans were given
wo different doses of monovalent CYD DENV-2, each raising
espectable levels of neutralizing antibodies against an Asian geno-
ype 1 DENV-2 strain which were durable for 12 months.[56] But,
t 12 months only 30–50% of vaccinees circulated antibodies to
he DENV-2 JaH strain (genotype 3) while around 70% retained
RNT antibodies to an American genotype DENV-2. No other
onotypic DENV vaccines were studied in humans. No humans
ere challenged to test monotypic protective immunity. These
enotype-dependent neutralizing antibody results may  underlie
he suggestion that the DENV-2 component of CYD 23 might have
rotected against infection only by Asian-American DENV-2 geno-
ype viruses [10]. Protection against DENV-4 disease in CYD 23 is
onsistent with observed pre-clinical data [53]. Presumably, this
rotection derives from antibodies and not from T cells. The dura-
ion of this protective immunity will be of interest.
Incomplete heterotypic immune protection. Based upon Sabin’s
bservations early symptomatic protective efﬁcacy might have
een expected to develop against DENV-2 disease following a
ingle dose of CYD 23 tetravalent vaccine as some protection
as raised against DENV-1 disease (Table 1). Data from mouse
odels and recent studies in humans suggest that T cell immu-
ity contributes importantly to protection against heterotypic
ENV infection. [37,38] Vaccines presenting yellow fever but not
ENV non-structural protein antigens to the immune system
ould not be expected to mount strong protective dengue T cell
esponses.Incomplete multitypic immune protection. In the CYD 23 trial, pro-
ection against DENV-2 disease did not increase after doses 2 and
. Given the relatively high mean titers of DENV-1–4 neutralizing
ntibodies observed after one, two or three vaccine doses in the (2013) 4501– 4507
serological  sampled group the absence of multitypic protective efﬁ-
cacy against DENV-1–4 disease is puzzling [10]. This is not the ﬁrst
time that neutralizing antibodies measured in Vero cells have failed
as a good correlate of protection [57]. The absence of DENV T cell
immunity in CYD vaccines is the best current explanation for the
lack of multitypic protective immunity.
4. Moving forward: mastering an empirical process
DENV vaccine developers in the present era have predicated
protection on classical dengue neutralizing antibody responses.
Inordinate effort, time and funds have been expended to dis-
cover that DENV neutralizing antibodies measured in conventional
in vitro systems are not a correlate of vaccine-induced protection.
4.1.  Pre-clinical testing
Pre-clinical  studies must include studies in which sub-human
primates immunized with monotypic vaccines are challenged no
earlier than six months after last vaccine dose using homotypic live
DENV (taking care to score protection as the absence of viremia plus
the absence of a four-fold boost in neutralizing antibodies).
4.2.  Phase I and II testing
Future  phase I and II tests should include challenges with live-
attenuated DENV, proceeding in a stepwise manner:
a. Phase I. Test each monovalent DENV vaccine for ability to raise
homotypic protective immunity. The author supports the recom-
mendation  of Durbin and Whitehead to use live DENV to test
protective  immunity. [58] All attenuated monovalent DENV vac-
cines should be challenged to establish protection of humans
using  homotypic live DENV using “solid immunity” as a response
criterion.
b. Phase II. Test tetravalent DENV vaccinees for protective immunity
by  challenge with monotypic live-attenuated DENV 1–4. This crit-
ical  study should anticipate results achieved in phase III trials.
Due  to the genetic and immunological heterogeneity of humans,
this  study must be performed in fairly large numbers of sub-
jects.  Challenge with monotypic DENV should occur no earlier
than  six months after immunization is completed. Individuals
given  a tetravalent vaccine in previous phase II studies can also
be  enrolled in challenge studies. Modiﬁed phase II trials are not
designed  to replace phase III clinical trials as only phase III or
IV  trials will identify dengue protective immunity in genetically
different human hosts with prior immunity to various non-DENV
ﬂaviviruses who  are tested by exposure to infection with differ-
ent  DENV strains and genotypes.
c. Reactogenic attenuated DENV strains available. The Walter Reed
Army  Institute of Research (WRAIR) has mildly reactogenic GMP
strains  of DENV-1 and DENV-3 available for human challenge
studies  [59].
d. Non-reactogenic challenge DENV strains available. The writer
recommends that demonstrably attenuated monotypic DENV
vaccine  candidates be used for challenge. These include the
live-attenuated DENV 1–4 derived at Mahidol University and
produced  at GMP  by sanoﬁpasteur [60]. If these strains are
selected,  care must be taken to ﬁnd a suitable attenuated DENV-
3  strain as the re-derived DENV-3 vaccine was fully virulent
when  given to susceptible adults [47,61]. Another panel of atten-
uated  GMP  DENV 1–4 are at the WRAIR. These were attenuated
by  serial passage in primary dog kidney cells and tested in
humans  of varying ages [9,62]. These two sets of attenuated
DENV have been given to a few DENV-immune individuals with-
out  any increase in reactogenicity [9,63]. Nor was increased
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reactogenicity observed with second doses of live-attenuated
DENV given to individuals with dengue antibodies raised by a
ﬁrst dose. This provides conditions for ADE to occur. Another set
of  attenuated DENV strains are the mutagenized DENV 1–4 at
the  National Institutes of Health, USA. These strains were inde-
pendently  tested for infectiousness, safety and immune response
in  susceptible human volunteers [3,24]. Use of live-attenuated
DENV should be able to build on the extensive experience with
yellow  fever 17D vaccination of humans [64,65].
.3.  Search for in vitro immune correlates of protection
. Characterize the immune responses to monotypic live-attenuated
DENV (challenge virus). Until dengue vaccine development efforts
cease  there will be an urgent requirement for a reliable in vitro
correlate  (or surrogate) of protective immunity. If live atten-
uated  virus challenge is undertaken for Phase I and II testing
of  DENV vaccine candidates an opportunity will be at hand
to  obtain “gold standard” markers of the protective immune
response when these strains are given to susceptible subjects.
Antibody studies might include but not be limited to: (1) identi-
ﬁcation  of attachment of neutralizing antibodies to type-speciﬁc
quaternary structures [26,27]; (2) enumerate early type-speciﬁc
antibody secreting cells (ASC) [36]; (3) identify concentrations
and avidity of type-speciﬁc convalescent neutralizing antibodies
and  (4) use a relevant Fc-receptor-bearing cell system to measure
the  balance between enhancing versus neutralizing antibodies
[39].  Studies on T cell immunity might include but not be limited
to  identifying the precise speciﬁcity, magnitude, breadth and
polyfunctional nature of the human CD8+ T cell response using
ELISPOT,  intracellular cytokine staining and tetramer staining
[37].  In mice, protective DC8+ T cell responses were correlated
with  IFN-gamma and TNF production and expression of CD 107a
marker  [12,66].
. Characterize the immune responses to monotypic DENV-1–4 vac-
cines.  Relevant in correlative vitro studies should be performed
on  susceptible individuals receiving monotypic DENV vaccines.
. Characterize the immune responses to a single dose of tetravalent
DENV  vaccine. Correlative tests of monotypic DENV protective
immunity should be applied to sera from individuals immunized
with  mixtures of four vaccine viruses.
.4.  Solve the interference problem
Any tetravalent DENV vaccine schedule that fails to protect
gainst all four challenge viruses deﬁnes an interference problem.
ecause there is no explicit understanding of DENV interference,
he solution to this problem can only be approached empirically.
he NIH team has led the way. Their mixtures of individually
ustomized mutant DENV have produced the highest trivalent or
etravalent neutralizing antibody responses following a single dose
f vaccine of any tetravalent DENV vaccine. [8] Step by step immu-
ization with one or more attenuated DENV or a prime-boost
trategy may  result in the type of protective immunity seen after
equential infections with two or more wild-type DENV. A full dis-
ussion of various options is beyond the scope of this paper.
.5.  Is protection against DENV NS1 required?
Cortisone given to Vietnamese children and adults early in the
ourse of severe dengue disease was designed to suppress the
athophysiological response to a T cell-mediated “cytokine storm”.
owever, this drug regimen failed to prevent or diminish dengue
ascular permeability. [67] This result raises the possibility that T
ell immunity does not trigger DHF/DSS but a completely different
athogenic mechanism may  be responsible. Is it possible that NS1
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contributes directly to the vascular permeability syndrome [68]?
Dengue NS1 interacts with the complement system; complement
split products have been considered as central to the vascular per-
meability syndrome [69–71]. It has been shown that during the late
stages of DHF NS1 circulates in human plasmas complexed with
thrombin [72]. In vitro, NS1 forms complexes with prothrombin
resulting in the prolongation of partial activated prothombin time,
a strong correlate of vascular permeability [72,73]. It is startling to
review the published data that describe how passively transferred
antibodies or active immunization with NS1 protected monkeys
from liver disease caused by yellow fever and prevented deaths
of mice infected with homotypic wild-type DENV [74–79]. A crash
program is needed to unequivocally rule in or rule out a direct role
for dengue NS1 in the pathogenesis of severe disease and its role as
a type-speciﬁc protective immunogen. It has long been postulated
that a vaccine against DENV NS1 might safely bypass the risk of
ADE. If such a vaccine prevents severe dengue disease this would
truly be a gift.
5.  Conclusion
In 2003, with funding from the Rockefeller and Gates Foun-
dations to the International Vaccine Institute, a basic dengue
virology/immunology research program (Pediatric Dengue Vaccine
Initiative) was designed and implemented. The PDVI had as its goal
the identiﬁcation of in vitro correlates of protection or enhance-
ment in sera after dengue vaccination. While considerable solid
research progress was made toward this goal during the tenure
of the program, the needed discriminatory tests still elude us. The
suggestions made in this review, if implemented, will unquestion-
ably add costs to the early stages of testing of candidate dengue
vaccines. Problems will arise concerning equitable and affordable
access to acceptable challenge virus strains. But, as argued here,
the quality of data obtained should save time and costs in clini-
cal tests of dengue vaccine efﬁcacy. For this reason there exists an
outstanding opportunity for those agencies dedicated to improving
international health to establish a program that will make available
to vaccine developers affordable challenge dengue viruses and to
support the efforts needed to identify in vitro correlates of protec-
tive immunity.
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